Agenda - Day 2

There are no agenda items with this track

7:45 am

7:45 am

Registration and Breakfast

8:30 am

8:30 am

Opening Remarks from the Chairs

8:45 am

8:45 am

Sponsor Panel Discussion:

Advance Your Company’s Emergency Preparedness with Lessons Learned During Covid-19

The Covid-19 pandemic has had a significant adverse impact across the pharmaceutical industry.  Improve your company’s emergency preparedness plans with lessons learned from Covid-19.  Take away actionable insights on:

  • How clinical trials were affected, the financial impact expected and how this can be avoided
  • Managing inventory and patients when the global supply chain is disrupted
  • What steps companies can take to prepare for the next major adverse public health event

Improve your company’s preparedness for the next major adverse public health event

9:30 am

9:30 am

INDUSTRY EXPERT:

Position Your Company to Succeed in the Next Decade with Market Access Metrics and Trends for 2020 and Beyond

The pharmaceutical industry has changed significantly over the past decade, and in many ways change will accelerate affecting most segments of the entire process from drug development to market access.  Prepare your company to adapt to changing market access realities with data-driven insights.  Develop an action plan to evaluate the strategic implications of ongoing change to help you:

  • Understand the factors likely to impact the timeline for your products’ development and prepare early for their seamless launch
  • Analyse how market trends are shaping up for all types of therapies to determine where your next opportunities lie
  • Assess how the increasing digitization of healthcare delivery will impact your relationships with patients and health professionals

Bolster your market access strategy for the next decade with a data-driven approach.

10:00 am

10:00 am

Morning Break

10:30 am

10:30 am

Panel Discussion

Explore New Approaches to Developing and Gaining Market Access for Drugs to Treat Rare Diseases

Developing, delivering and funding treatment for patients with rare diseases has become the single biggest challenge for payers, patients and manufacturers. With a growing consensus that a new drug development model is needed, the question becomes what form should it take? Gain valuable insights to inform your market access strategy by:

  • Learning what types of partnerships and funding will be key to the successful development of drugs for rare diseases going forward
  • Hearing what impact the increased government funding announced in last fall’s federal budget is having on the pipeline of treatments
  • Understanding what new routes to market and commercialization for these medications may be forged to get them to patients safely and expeditiously

Prepare your organization for a new market access model for treatments for rare diseases.

11:15 am

11:15 am

Case Study

Be Prepared for the Next Level in Drug Development and Discover How Open Science is Transforming the Treatment of Rare Diseases

The collaborative model of Open Science applied to drug has the potential to save the lives of many patients suffering from a rare disease. Gain valuable insights into how this development model works and why it is poised to expand. Take back to your office actionable insights to help you:

  • Understand how this new model works and its potential contribution to the healthcare system
  • How patients can access live-saving treatments not previously available
  • The implications Open Science has for the industry going forward as it gains traction

Improve your understanding of how Open Science is transforming drug discovery.

11:45 am

11:45 am

INDUSTRY EXPERT:

Predictive Analytics in Patient Support – Fact or Fiction?

There is a lot of buzz around harnessing historic trends and patterns in patient data – is it hype or reality?  Many wonder if it will impact PSP design and implementation and whether patients will benefit.  Take away a plan to understand:

  • What is predictive analytics in the PSP environment?
  • What is the impact on patient engagement?
  • Can informed analytics impact patient outcomes?

Understand how predictive analytics in patient support could help your organization.

12:15 pm

12:15 pm

Networking Luncheon

1:00 pm

1:00 pm

Luncheon Keynote Address

Gain Valuable Insight into the Current Status of National Pharmacare to Prepare Your Organization

Last fall, a national pharma care program inched closer to reality with the “Final Report of the Advisory Council on the Implementation of National Pharmacare”.  Get the latest information on how this ground-breaking initiative is progressing.  Update your market access strategy with the latest intelligence on:

  • What progress is being made toward establishing the Canadian Drug Agency
  • What approaches are being discussed about introducing the new national formulary
  • How the federal government is following-up on its $1billion pledge on funding for rare diseases in the 2019 budget

Be prepared to adapt your market access strategy to new realities under national pharmacare

1:30 pm

1:30 pm

Current Considerations in Implementing the National Pharmacare Program in a Post-pandemic World

Last fall, a national pharma care program inched closer to reality with the “Final Report of the Advisory Council on the Implementation of National Pharmacare”. Get the latest insights and information on this ground-breaking initiative in a post-pandemic world. Update your market access strategy with the latest intelligence on:

  • The establishment of the Canadian Drug Agency
  • What approaches are being discussed about introducing a new national formulary
  • The financial impact of Covid-19 on the government’s $1billion pledge on funding for rare diseases in the 2019 budget

Adapt your market access strategy to the latest developments in Canada’s national pharmacare program

2:00 pm

2:00 pm

Panel Discussion

Improve Your Assessment of the Medical Cannabis Market with the Latest Pharmacoeconomics and Health Canada Policy Developments for Pharmacies

The use of medical cannabis has continued to increase in tandem with greater knowledge concerning its effectiveness in treating various disorders. Decisions regarding whether your organization should include it in your pipeline or formulary need to be backed by an evidence-based approach. Discover the latest developments in the use of medical cannabis to assist you to:

  • Better understand the opportunities this market represents and evaluate whether the benefits of entering it outweigh the risks of staying out
  • Assess the growing body of evidence that supports the use of medical cannabis especially among older patients
  • Gain insight into how Health Canada is moving forward with policies for cannabis products in pharmacies

Benefit your organization with an evidence-based approach to decisions on medical cannabis

2:45 pm

2:45 pm

Afternoon Break

3:15 pm

3:15 pm

Case Study

Benefit Plan Performance; Advance Your Market Access Plans with Insights on Plan Sponsors’ Demands for Sustainability

The increased scrutiny plan sponsors are applying before including medications on their formularies is also now being applied to plan performance. Heighten your awareness of how plan sponsors intend to achieve sustainability. Adapt your market access strategy by:

  • Understanding why sponsors are increasingly turning to third-parties to analyze their spending
  • Gaining insights into where plan sponsors have uncovered the greatest inefficiencies
  • How the use of more granular data will drive plan design in the future

Give your market access strategy an edge with insights on new plan performance analysis.

3:45 pm

3:45 pm

Industry Expert;

What’s Next for Patient Support Programs?

Patient support programs to allow patients access to specialty medications have now become a mainstay in the marketplace over the past couple of decades. However, there are shifting market dynamics that will likely require your company to develop a new approach to these critical programs. Gain insight that will allow your company to take incisive steps in forward planning by:

  • Understanding what tensions are now surfacing between support services required and financial sustainability
  • Determining to what extent the entry of biosimilar PSPs increase competition
  • Hearing what vision may be emerging in how PSPs could be re-designed

Gain an edge in patient retention with an improved PSP

4:15 pm

4:15 pm

Case Study – New Technology

Learn How Using Blockchain Technology Can Improve Clinical Trial Data for Drug Submissions and Ultimately Market Access

When applied to clinical trials, blockchain technology has the potential to improve data integrity, transparency and reliability that will serve to expedite the progress of your new drug submissions. Evaluate the benefits that adopting this technology could have on your drug submissions and time to market. Enhance your market access strategy by learning:

  • What is the current status of the use of this technology within the pharma industry
  • How to conduct a cost/benefit analysis regarding adopting blockchain
  • Whether there is an advantage in adopting it now rather than waiting for the rest of the industry to catch up

Understand and evaluate the benefits of using blockchain technology for clinical trial data.

4:45 pm

4:45 pm

Conference concludes

Get the latest news

*Privacy Policy